New dual CDK approach tackles drug-resistant breast cancer
A new preclinical study suggests that combining next-generation CDK2 inhibitors…
A new preclinical study suggests that combining next-generation CDK2 inhibitors with existing CDK4/6 therapies could overcome drug resistance in breast cancer, delivering durable tumour control across multiple subtypes.




